Effective on May 29, 2025, China's NMPA, SAMR, and Ministry of Finance introduced enhanced measures to reward internal informants reporting serious quality or safety violations in the pharmaceutical and medical device sectors.
The regulation further strengthens protections against employer retaliation, ensures confidentiality, and extends eligibility to former employees. Employers are prohibited from altering or rescinding labor contracts or disclosing any information identifying the informant without consent. Whistleblowing now prevails over confidentiality or contract clauses, reinforcing transparency, compliance, and public health oversight.